Wednesday, September 23, 2026
← Back to archivePolicy
Policy•Endpoints News•Sep 22, 2026
Compounder Empower receives FDA warning letter over GLP-1s
background ▾
- •FDA's third warning letter to Empower Pharmacy indicates persistent compliance failures in compounded GLP-1 manufacturing, raising questions about the company's ability to remediate or face further enforcement (product seizures, injunctions).
- •This action underscores FDA's intensified oversight of compounders in the high-volume GLP-1 market, likely to influence other compounders' manufacturing and quality practices.
- •Watch for: full warning letter details (manufacturing defects, sterility/potency issues, or labeling violations), Empower's response timeline, and whether FDA pursues additional enforcement or product recalls.
Empower PharmacyGLP-1 (weight loss treatments)
→ Read original articlePolicy•KFF•Sep 23, 2026
KFF/AP Survey Probes Rural Voters’ Increasing Anxieties About the Rising Cost of Living, Including Health Costs, Heading into the Midterm Elections
background ▾
- •Rural voters—traditionally Republican supporters—are experiencing increased economic stress and higher healthcare costs that may dampen their midterm election enthusiasm
Policy•STAT News•Sep 23, 2026
Opinion: Mentally ill women deserve more support to have children
background ▾
- •Severe gaps exist in reproductive psychiatry access: only 6-10 reproductive psychiatrists estimated in Michigan, 20% of women with serious mental illness are uninsured, and psychiatric care deserts persist in rural areas
Antipsychotics (unspecified)SSRIs (Selective Serotonin Reuptake Inhibitors)
→ Read original articlePolicy•KFF•Sep 22, 2026
The Trump Administration’s Foreign Aid Review: Status of the President’s Malaria Initiative (PMI)
background ▾
- •USAID dissolution and foreign aid freeze have directly disrupted PMI operations and other U.S. global health programs with limited legal remedies available to date
- •Responsibility for remaining global health programs transferred to State Department, signaling organizational and operational uncertainty for ongoing initiatives
- •Proposed HHS cuts and reorganization pose additional risk to pharmaceutical supply chains and malaria treatment programs dependent on U.S. funding and coordination
Policy•KFF•Sep 22, 2026
Implementation of Medicaid Immigrant Eligibility Restrictions Under the 2025 Reconciliation Law: Issues to Consider
background ▾
- •Medicaid and CHIP eligibility will narrow substantially on October 1, 2026, restricting coverage primarily to green card holders and exempt groups, eliminating eligibility for approximately 100,000 currently covered lawfully present immigrants by 2034
- •CBO estimates $6.2 billion federal spending reduction, but actual coverage losses may exceed projections due to administrative friction and documentation challenges affecting eligible individuals
- •States face significant implementation burdens including system changes, eligibility verification requirements, and disenrollment processing while managing collateral coverage losses among eligible populations
Market Access
Market Access•Fierce Biotech•Sep 23, 2026
GSK aiming to ‘balance West and East’ after Hansoh deal success showed China’s potential
background ▾
- •GSK's strategic licensing deals with Chinese partners (Hansoh, Hengrui) are yielding clinical validation; ris-rez achieved 18.5-month median OS in phase 3 lung cancer trial, positioning it competitively against Amgen and Merck
- •Major capital commitments signal industry confidence: GSK's $12 billion biobucks deal with Hengrui and $1 billion Aiolos acquisition reflect belief in China's drug development quality and speed
- •Geopolitical headwinds pose execution risk: U.S. policymaker rhetoric on restricting China's biotech growth could threaten deal economics and partnership viability despite near-term clinical success
GSKHansoh PharmaHengrui Pharmaceuticalsris-rezAIO-001
→ Read original articleMarket Access•Fierce Biotech•Sep 22, 2026
Novartis secures new radioligand in $900M deal as competition strengthens
background ▾
- •Radioligand market leadership is shifting from a Novartis duopoly toward a multi-player competitive landscape, with Telix consolidating supply chain and pipeline assets via major M&A
- •Novartis's $900M licensing deal with BoomRay targets fibroblast activation protein and Nectin-4 in solid tumors, while competitive ITM-11 program faces FDA manufacturing deficiencies but plans resubmission—regulatory outcome and Telix acquisition closure timing are critical watch points
- •Monitor Telix-ITM integration execution, BoomRay program advancement timelines, and whether other players (Lantheus, Bayer) accelerate radioligand acquisitions or internal development in response to this consolidation wave
NovartisBoomRay TherapeuticsTelix PharmaceuticalsPluvictoLutatheraITM-11
→ Read original articleMarket Access•Fierce Biotech•Sep 22, 2026
Lexeo takes up the Mantle in $8M acquisition for Friedreich ataxia assets
background ▾
- •Lexeo acquires four Friedreich ataxia assets from Mantle for $8.3M upfront plus $13M milestones, positioning LX3010 (oral combination therapy) as a potential complementary approach to its lead AAV gene therapy LX2006.
- •Three new strategic collaborations with Weill Cornell Medicine, Vivet Therapeutics, and Apertura Gene Therapy address critical technical barriers to repeated AAV dosing and CNS delivery—a major unmet need in FA treatment.
- •Watch for: Lexeo's program prioritization announcement (early 2025), IND submission (2027), and LX2006 pivotal trial topline data (H2 2027), which could establish the first disease-modifying gene therapy for FA cardiomyopathy.
Lexeo TherapeuticsMantle TherapeuticsWeill Cornell MedicineLX3010LX2006LX3030
→ Read original articleMarket Access•Fierce Biotech•Sep 22, 2026
Siemens Healthineers and Novo team up on fatty liver disease awareness, testing
background ▾
- •Siemens and Novo are collaborating to drive earlier MASH diagnosis through non-invasive blood testing and disease awareness campaigns, addressing a major clinical gap where <25% of at-risk patients are currently identified.
- •The partnership positions both companies' commercial products—Siemens' ELF Test and Novo's Wegovy—within a broader care pathway, potentially expanding addressable patient populations through earlier triage and intervention strategies.
Siemens HealthineersNovo NordiskMadrigal PharmaceuticalsWegovy (semaglutide)Rezdiffra (resmetirom)ELF Test
→ Read original articleMarket Access•Endpoints News•Sep 22, 2026
Novo's CEO knows the drugmaker needs to build confidence
background ▾
- •Novo Nordisk's capital markets presentation failed to generate strong investor enthusiasm, indicating potential concerns about strategy articulation or execution confidence
Novo Nordisk
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Sep 23, 2026
Roche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease market
background ▾
- •Sefaxersen met its primary endpoint of statistically significant UPCR reduction at Week 37 interim analysis, supporting potential accelerated approval pathway in IgAN.
- •Direct competitive positioning against Novartis Fabhalta in a high-growth IgAN market; sefaxersen's monthly dosing and cholesterol safety profile differentiate from twice-daily oral competitor.
- •Roche projects peak sales of €1-2 billion versus analyst consensus of €400 million by 2030; regulatory path and final phase 3 kidney function data (Week 105) are critical inflection points.
RocheIonis PharmaceuticalsNovartissefaxersenFabhaltaIONIS-FB-LRx
→ Read original articleClinical Trials•Fierce Biotech•Sep 23, 2026
Anaconda Biomed snares $56M in funding for endovascular tech
background ▾
- •Anaconda secured $53M to complete the Athena pivotal trial for its ANA Funnel Catheter in acute ischemic stroke, with the majority of funding directed toward trial completion
- •The device addresses a specific unmet need in large vessel occlusion stroke treatment, and positive pivotal results could support regulatory submissions in major markets
- •Watch for Athena trial readout timing and subsequent FDA/EMA regulatory strategy announcements; competitive landscape with established thrombectomy device makers remains an execution risk
Anaconda BiomedOmega FundsCOFIDESANA Funnel Catheter
→ Read original articleClinical Trials•Fierce Biotech•Sep 22, 2026
Celldex monoclonal antibody rebounds with pair of phase 3 wins for chronic skin condition
background ▾
- •Barzolvolimab met both primary and secondary endpoints in two phase 3 CSU trials, with 55.3% of omalizumab-refractory patients achieving complete response at week 12 with the 150-mg dose versus 9.3% placebo—a clinically meaningful advantage in a population with high unmet need.
- •The safety profile appears favorable with only 2 cases of anaphylaxis out of ~1,939 patients and 16% discontinuation rate (mostly patient withdrawals), supporting potential competitive positioning against Xolair.
- •Celldex faces near-term competitive pressure from Cue Biopharma's CUE-221, which hit its phase 2 endpoint yesterday and is moving to phase 2b/3; market share and differentiation will depend on comparative efficacy/safety data and physician/payer preference for mechanism of action.
CelldexGenentechNovartisbarzolvolimabXolairomalizumab
→ Read original articleClinical Trials•Fierce Biotech•Sep 22, 2026
Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win
background ▾
- •Dazodalibep met its primary endpoint in OASIZ 301, demonstrating rapid and sustained improvement in systemic disease activity—the first positive readout for the CD40L mechanism in Sjögren's and a validation of the target after multiple industry setbacks
- •FDA approval will likely require two positive phase 3 results; OASIZ 303 outcome in a milder patient population remains critical, and results are not yet available
- •Watch for OASIZ 303 data and competitive pressure from Novartis's ianalumab (which achieved two phase 3 wins despite strong placebo effects), plus regulatory guidance on what constitutes sufficient evidence for this orphan-like indication
AmgenHorizon TherapeuticsViela Biodazodalibepianalumabadezkibart
→ Read original articleClinical Trials•Fierce Biotech•Sep 22, 2026
Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint
background ▾
- •Ulefnersen met its primary endpoint in Phase 3, demonstrating clinically meaningful slowing of disease progression in FUS-ALS with favorable tolerability, positioning the program for expedited FDA review.
- •Secondary endpoints also achieved statistical significance, including effects on neurodegeneration biomarkers, time to death, and permanent ventilation, strengthening the clinical profile.
- •Watch for FDA interactions and potential breakthrough therapy or fast-track designation; commercial opportunity remains severely limited by disease rarity (0.6% of ALS cases), despite unmet medical need in a rapidly progressive pediatric population.
Otsuka PharmaceuticalIonis Pharmaceuticalsulefnersen
→ Read original article